Comparative Pharmacology
Head-to-head clinical analysis: FLUOROMETHOLONE versus STERANE.
Head-to-head clinical analysis: FLUOROMETHOLONE versus STERANE.
FLUOROMETHOLONE vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce phospholipase A2 inhibitory proteins, thereby reducing prostaglandin and leukotriene synthesis. Exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
1-2 drops of 0.1% suspension in conjunctival sac 2-4 times daily; severe cases: every 4 hours initially, then taper. Ointment: 0.5 inch ribbon 1-3 times daily.
100 mg orally every 12 hours
None Documented
None Documented
Clinical Note
moderateFluorometholone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin."
Clinical Note
moderateFluorometholone + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin."
Clinical Note
moderateFluorometholone + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 1.3–2.2 hours; However, the pharmacodynamic half-life (duration of adrenal suppression) is longer (~24–36 hours) due to receptor-mediated effects.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal (primarily as metabolites): ~70%; Fecal: ~20%; Unchanged in urine: <5%
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category A/B
Category C
Corticosteroid
Corticosteroid
Fluorometholone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin."